Pelacarsen, the first drug designed to lower Lp(a) to complete a cardiovascular outcomes trial, cut Lp(a) by 78% but did not reduce cardiovascular deaths, heart attacks, strokes or urgent coronary procedures compared with placebo. Novartis announced the topline result on 4 September 2026; the full results were presented at the American Heart Association's Scientific Sessions on 7 November 2026 and published the same day in the New England Journal of Medicine.123 "I cannot avoid the disappointing conclusion – it didn't work," said Steven Nissen of Cleveland Clinic, the trial's senior author.2 If your Lp(a) is high, the link between the number and risk has not changed: US guidelines still say to measure it once, and a high level is still associated with higher risk. What is now less certain is whether lowering Lp(a) with a drug reduces that risk.45 The timeline is what changed. No drug is approved to lower Lp(a), and the next answers will come from four other outcome trials whose estimated completion dates run from 2028 to 2031.678
This page covers what the trial found, why the investigators and other experts say it does not settle the question for the next drugs, what lowers Lp(a) today, and what to do with a high result now. If you are new to the marker itself, start with what a high Lp(a) means.
What Lp(a)HORIZON tested and found
The trial randomized about 8,300 adults aged 18 to 80 with established cardiovascular disease and an Lp(a) of at least 70 mg/dL, at 797 sites in 42 countries. Established disease meant a heart attack or ischemic stroke between 3 months and 10 years before screening, or symptomatic peripheral artery disease; 82% had had a heart attack. Their mean age was about 60, 27% were women and 26% had diabetes.92 Participants got an 80 mg injection of pelacarsen or a placebo once a month, on top of their usual lipid-lowering and blood pressure treatment.91 The primary endpoint combined cardiovascular death, non-fatal heart attack, non-fatal stroke and urgent coronary revascularization requiring hospitalization. It was tested in everyone and, separately, in people with Lp(a) of 90 mg/dL or higher.9
The results, over a median follow-up of 57 months (4.7 years):10
| Measure | Pelacarsen | Placebo |
|---|---|---|
| Primary endpoint, everyone (Lp(a) 70 mg/dL or more) | 511 of 4,157 (12.3%) | 503 of 4,165 (12.1%) |
| Hazard ratio | 1.02 (95% CI 0.90 to 1.15) | Reference |
| Primary endpoint, Lp(a) 90 mg/dL or more | 402 (12.3%) | 403 (12.3%) |
| Hazard ratio | 1.00 (95% CI 0.87 to 1.15) | Reference |
| Change in Lp(a) at one year | −78.4% | −3.2% |
| LDL cholesterol at one year | 62.3 mg/dL | 71.2 mg/dL |
| Stopped treatment because of an adverse event | 20.6% | 7.5% |
| Serious adverse events | 37.3% | 41.1% |
Sources: Cleveland Clinic, home of the trial's senior author, and the American Heart Association, both reporting the New England Journal of Medicine paper.111023 A hazard ratio of 1.00 means the same rate of events in both groups; the confidence interval shows the range of effects compatible with the data.
A few more findings matter for reading the result:
- Lp(a) stayed well below baseline. The median starting level was 236 nmol/L (109 mg/dL).2 Averaged over the trial, the reduction with pelacarsen was 73.9%, even though 35.1% of people on pelacarsen stopped the drug early for any reason, against 18.3% on placebo.1213
- No secondary endpoint moved either. The combination of heart attack, stroke or cardiovascular death, the coronary-only combination, coronary death and death from any cause did not differ between the groups.2
- Side effects were the main difference. Flu-like symptoms, injection-site reactions and allergic reactions were more common on pelacarsen, and 19 people on pelacarsen had anaphylaxis, against none on placebo; none died of an allergic reaction.2
- Extended analyses agreed. In the analyses published in NEJM Evidence, the hazard ratio was 0.98 (95% CI 0.85 to 1.12) in participants while on treatment and 1.09 (0.89 to 1.34) in those whose treatment was never interrupted, and the rate ratio for first and recurrent events combined was 1.00 (0.87 to 1.14). Nissen said the results were "completely neutral across multiple analyses."13142
"These are not the results we hoped for," Shreeram Aradhye, Novartis's chief medical officer, had said at the topline announcement in September.1
Does this change what a high Lp(a) means for you?
The National Lipid Association says no. In its statement after the announcement, the National Lipid Association said Lp(a) "remains an important and independent risk factor" for atherosclerotic cardiovascular disease, that "clinicians and patients should continue to measure Lp(a)," and that people with elevated levels should have their other risk factors managed intensively.4
The association between Lp(a) and risk comes from population and genetic studies, not from drug trials. The 2022 European Atherosclerosis Society (EAS) consensus concluded that studies of hundreds of thousands of people support a causal and continuous link between Lp(a) concentration and cardiovascular outcomes.15 The 2026 ACC/AHA guideline puts numbers on it: an Lp(a) of 125 nmol/L or 50 mg/dL or higher is associated with about a 1.4-fold higher long-term risk of heart attack or stroke, and 250 nmol/L with at least a two-fold higher risk.5
Not everyone agrees. "Do we still need to measure Lp(a) in everyone? Another example of the guidelines getting ahead of the evidence," cardiologist David L. Brown posted on X.16 In JAMA's news coverage, UCSF cardiologist Rita Redberg said the result is a chance "to question the importance of having outcomes data before we start embracing another measurement," and described seeing healthy people with a high Lp(a) and very low overall risk who were very anxious.17 Deepak L. Bhatt of Mount Sinai, who reports research funding from Novartis, framed the open question: "The key question is whether it is a modifiable mediator of risk, or merely a marker."6
Why experts say one result does not settle it for the other drugs
The full data rule out one explanation, that Lp(a) did not come down, and leave the others open. A review in The American Journal of Medicine in October, written before the full results, lists the candidates: treatment after long cumulative exposure to Lp(a), already advanced artery disease, intensive background prevention, the size and duration of Lp(a) suppression, who was enrolled, their baseline risk, and biological differences between patients.18 Here is what each argument rests on.
How far Lp(a) came down
In phase 2, pelacarsen cut Lp(a) by an average of 72% at 60 mg every 4 weeks and 80% at 20 mg every week.19 In HORIZON, at 80 mg once a month, the drop was 78.4% at one year.10 The siRNA drugs went further in their phase 2 trials: placebo-adjusted reductions of 97% to 101% for olpasiran at its higher doses, 94% for lepodisiran, and 81% to 86% for zerlasiran.202122 These trials used different doses, time points and assays, so the figures are not a head-to-head comparison.
Why the gap might matter: genetic studies suggest that the benefit of lowering Lp(a) depends on the absolute drop in mg/dL, not the percentage. One estimated that about 100 mg/dL less Lp(a) would match the benefit of lowering LDL cholesterol by 38.67 mg/dL (1 mmol/L); another put the figure at about 66 mg/dL.2324 For scale, at the trial's median starting level of 109 mg/dL, a 78% cut removes about 85 mg/dL, within the range those estimates point to (about 55 mg/dL at the 70 mg/dL entry minimum). Yet in the extended analyses, people whose Lp(a) fell by more than the median of 170 nmol/L did no better than placebo (hazard ratio 1.09, 95% CI 0.92 to 1.29), and neither did those who reached a level below the median of 69.5 nmol/L (1.10, 0.93 to 1.29).213 That weakens the argument that the drop was simply too small, without ruling out that the siRNAs' deeper and steadier lowering behaves differently. Analysts at Citi wrote after the topline result, "We would not declare the mechanism dead," adding that "[g]reater target suppression could matter if cardiovascular benefit requires crossing a biological threshold."25
How the drug was given
Before the full results, Michelle O'Donoghue of Brigham and Women's Hospital, principal investigator of the olpasiran phase 3 trials, noted in JAMA that pelacarsen has a much shorter half-life than the siRNAs, which could have made Lp(a) levels fluctuate during the trial. She also suggested that giving it less often and at a higher dose than in phase 2 could have hurt tolerability.17
Who was treated, and when
Everyone in the trial already had cardiovascular disease and was on guideline-directed treatment; LDL cholesterol at one year was around 62 to 71 mg/dL in the two groups.110 Nissen noted that the trial did not test prevention in people without cardiovascular disease, and that its result applies to pelacarsen only.12 Bhatt offered several possibilities, including "It could be the specific drug" and "It could be that Lp(a) levels were not high enough at baseline," and said strong LDL control may have left little room to show an extra benefit.6 Donald Lloyd-Jones of Boston University said, "Maybe we need to start with a younger population and treat longer to really see an effect," and that differences between trial populations may matter more than differences between drugs.17
Who stayed in the trial
In October, François Mach, principal investigator at the trial's Geneva site, told JAMA that about half the participants at his site and at a colleague's site in Basel had withdrawn, and that he strongly suspected most were in the pelacarsen group.17 Withdrawal for any reason is not the same measure, but the trial-wide figures confirm that tolerability differed: 20.6% of people on pelacarsen stopped it permanently because of an adverse event, against 7.5% on placebo.11 The analysis limited to participants while on treatment was also neutral (hazard ratio 0.98).1314
Or lowering Lp(a) may simply not help
That remains possible, and the next trials are designed to answer it. Nissen said the trial "is not the end of the story," adding that "a single trial does not provide definitive evidence of a lack of benefit of lowering lipoprotein(a)."101213 Bhatt's view after the topline result: "I strongly feel that the ongoing trials should continue until their planned end."6
The Lp(a) drugs still in trials
Pelacarsen is an antisense oligonucleotide; olpasiran, lepodisiran and zerlasiran are small interfering RNAs (siRNAs). All four reduce the liver's production of apolipoprotein(a), the protein that defines Lp(a). Muvalaplin is a daily pill that blocks the Lp(a) particle from forming.1526 Pelacarsen is no longer one of them: after the full results, Novartis said it "has decided to discontinue the pelacarsen atherosclerotic cardiovascular disease (ASCVD) development program," including its ongoing studies and its managed access program, which the registry lists as no longer available.2728
| Drug (sponsor) | Type | Phase 2 Lp(a) lowering | Outcome trial | Estimated primary completion (registry) |
|---|---|---|---|---|
| Olpasiran (Amgen) | siRNA, injection every 12 weeks | 97–101% at higher doses | OCEAN(a)-Outcomes, 7,297 enrolled | March 2028 |
| Olpasiran (Amgen) | Same drug, first-event prevention | Same as above | OCEAN(a)-PreEvent, about 11,000 planned | October 2031 |
| Lepodisiran (Lilly) | siRNA, injection | 94% | ACCLAIM-Lp(a), 17,300 planned | March 2029 |
| Muvalaplin (Lilly) | Oral daily pill | 82–86% at 60–240 mg a day (intact Lp(a) assay) | MOVE-Lp(a), 10,450 planned | March 2031 |
| Zerlasiran (Silence) | siRNA, injection | 81–86% | None registered | No outcome trial yet |
| Pelacarsen (Novartis/Ionis) | Antisense, monthly injection | 72–80% at the top two doses | Lp(a)HORIZON, completed | July 2026 (actual); no reduction in events (HR 1.02); development discontinued |
Phase 2 figures are placebo-adjusted where the paper reports them that way; trial sizes and dates are from each registry entry, checked on 23 October 2026, and the HORIZON result is from the November 2026 publication.202126221972930891127
Who each trial enrolls matters if you want to know whether its result will apply to you:
- OCEAN(a)-Outcomes: adults 18 to 85 with a prior heart attack or coronary stent procedure and Lp(a) of at least 200 nmol/L. Its primary endpoint is coronary death, heart attack or urgent coronary revascularization, with no stroke component.7
- OCEAN(a)-PreEvent: adults 50 or older with no prior heart attack or stroke, multiple risk factors or evidence of atherosclerosis, and Lp(a) of at least 200 nmol/L.29
- ACCLAIM-Lp(a): Lp(a) of at least 175 nmol/L, with either established disease or, from age 55, high risk without a prior event.30
- MOVE-Lp(a): Lp(a) of at least 175 nmol/L, with an event in the last 10 years or high risk, which can include a high coronary calcium score.8
Registry dates are the sponsors' estimates and can move. For scale, HORIZON's registry entry lists primary completion on 16 July 2026; the topline result came seven weeks later and the full publication four months later.913 Amgen also lists an olpasiran expanded access program, saying requests "may be considered" for adults with elevated Lp(a) and atherosclerotic cardiovascular disease.31 Silence Therapeutics, as of March 2026, called zerlasiran a "Phase 3 ready program" that is "well positioned for a potential third-party partner to initiate Phase 3 development."32
What lowers Lp(a) today, and what does not
- Dedicated Lp(a) drugs: none approved.6
- PCSK9 inhibitors (evolocumab, alirocumab): lower Lp(a) by roughly 15–30%, per the EAS; in the FOURIER trial, evolocumab's median reduction was 26.9%.1533 They are prescribed to lower LDL cholesterol and are not registered for Lp(a) lowering.15
- Statins: may raise Lp(a) slightly; the evidence is mixed. A pooled analysis of six trials found average increases of 8.5% to 19.6% on statins, while a meta-analysis of 39 trials found no clinically important difference from placebo.3435 The EAS consensus says statins should not be discontinued on that account, because the benefit in people with high Lp(a) far outweighs any risk from a modest rise. Do not stop or change a statin without talking to your prescriber.15
- Niacin: not recommended for Lp(a) lowering, because two outcome trials showed no clinical benefit.15
- Lifestyle: minimal effect on Lp(a), which is more than 90% determined by genes.515 Diet and exercise still lower LDL cholesterol, which is the lever guidelines point to; see how to lower cholesterol without medication.
- Lipoprotein apheresis: a procedure that removes lipoproteins from the blood, lowering both Lp(a) and LDL cholesterol. Its FDA indication covers high-risk people with familial hypercholesterolemia and coronary or peripheral artery disease whose Lp(a) stays at 60 mg/dL or higher and LDL cholesterol at 100 mg/dL or higher despite maximally tolerated lipid-lowering therapy.36
What to do with a high Lp(a) result now
- Know your number and its unit. The EAS and NLA treat below 30 mg/dL (75 nmol/L) as low risk and 50 mg/dL (125 nmol/L) or higher as high risk, with an intermediate zone in between.1536 There is no exact conversion between the two units: the EAS advises against a standard factor because assays vary so much, and calls 2 to 2.5 only a "best guess."15 You can convert your result between nmol/L and mg/dL as a range. The unit matters for trials too: HORIZON used mg/dL, while the olpasiran, lepodisiran and muvalaplin trials set cut-offs of 175 or 200 nmol/L.
- One test is usually enough. Levels stay relatively stable over a lifetime, so the 2026 guideline says repeat testing is generally not needed.537
- Work on what can change. The NLA recommends early, more intensive risk-factor management for people with elevated Lp(a), primarily aimed at LDL cholesterol.36 The EAS adds that every other cardiovascular risk factor should be addressed: LDL cholesterol and ApoB, blood pressure, smoking and diabetes.15 A coronary calcium scan shows whether calcified plaque has already formed; the ACC's summary of the 2026 guideline says it is recommended selectively, to refine risk when the usual estimate is uncertain.38
- Tell your first-degree relatives. Because the level is inherited, the NLA recommends cascade screening of parents, siblings and children of people with elevated Lp(a).36
- Bring the trial question to your clinician. Whether a trial or expanded access makes sense depends on your history, your number and your other treatment. The registry pages above list the eligibility criteria.
- Know what the next answer is. HORIZON tested one drug in people who already had cardiovascular disease. The next outcome result due is olpasiran's OCEAN(a)-Outcomes, with an estimated primary completion in March 2028; until then, no trial has shown that lowering Lp(a) with a drug prevents heart attacks or strokes.712
If your Lp(a) was measured at different labs, the numbers may not match even though your biology did not change. Merios Plus reads the PDF or photo of each lab report and keeps every Lp(a) result with the unit and reference range printed on that report, next to the LDL cholesterol and ApoB history you are actually working on. Because there is no exact conversion between nmol/L and mg/dL, compare results from the same unit and assay where you can, and ask your clinician before reading a gap between two labs as a change in your Lp(a).